« previous next »
Pages: [1]

Author Topic: (Abst.) Nasal foralumab shows promise in nonactive SPMS (CMSC annual meeting)  (Read 25 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9542
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Nasal foralumab shows promise in nonactive SPMS (CMSC annual meeting)
« on: June 27, 2022, 06:45:53 pm »

This abstract of a paper presented by researchers at Harvard University involves only one patient, but this statement in the abstract is worth noting:


Quote
There are no effective treatments for non-active secondary progressive MS (SPMS), which is mediated by compartmentalized CNS inflammation, including activated microglia.


From the recent CMSC conference (June 2, 2022)--"Nasal anti-CD3 monoclonal antibody (Foralumab) reduces PET microglial activation and blood inflammatory biomarkers in a patient with nonactive  secondary progressive MS":


https://cmsc.confex.com/cmsc/2022/meetingapp.cgi/Paper/8395

From MedPage Today (July 8, 2022), a brief commentary by Lawrence Steinman, MD, of Stanford University, on this research. The video may not be available but the transcript of his remarks is--entitled "Nasal Anti-CD3 Monoclonal Antibody Shows Promise in Progressive MS":

https://www.medpagetoday.com/meetingcoverage/cmscvideopearls/99454



« Last Edit: July 08, 2022, 09:17:34 am by agate »
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
2 Replies
192 Views 		Last post May 14, 2018, 08:47:09 pm
by agate
0 Replies
30 Views 		Last post September 15, 2020, 08:57:39 pm
by agate
0 Replies
38 Views 		Last post April 11, 2021, 08:59:30 pm
by agate
0 Replies
14 Views 		Last post November 15, 2021, 09:20:43 pm
by agate
0 Replies
23 Views 		Last post April 28, 2022, 08:43:27 pm
by agate